GT Biopharma (GTBP) Interest Expenses (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Interest Expenses of $63000.0 for Q1 2026, down 91.92% year-over-year from $780000.0 in Q1 2025, and down 99.51% quarter-over-quarter from $12.9 million in Q4 2025.
GT Biopharma (GTBP) Interest Expenses (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Interest Expenses for 17 consecutive years, with $63000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 91.92% year-over-year to $63000.0; the TTM figure through Mar 2026 stood at $275030.0 (down 64.74% YoY), while the FY2025 annual figure was $141.1 million, up 25.78% from the prior year.
- Interest Expenses fell to $63000.0 in Q1 2026 per GTBP's latest filing, from $12.9 million in the prior quarter.
- Across five years, Interest Expenses topped out at $217.0 million in Q2 2022 and bottomed at $30.0 in Q1 2024.
- Historically, Interest Expenses has averaged $36.9 million across 5 years, with a median of $6.8 million in 2025.
- Annual changes were most pronounced in 2024 — Interest Expenses plunged 99.99% — and 2025, when it surged 2599900.0%.
- GT Biopharma's Interest Expenses stood at $108.9 million in 2022, then slumped by 99.92% to $92000.0 in 2023, then jumped by 121839.13% to $112.2 million in 2024, then plunged by 88.5% to $12.9 million in 2025, then tumbled by 99.51% to $63000.0 in 2026.
- Business Quant data shows GTBP's Interest Expenses at $63000.0 in Q1 2026, $12.9 million in Q4 2025, and $281000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | 63,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63,000.00 |
| Mar 31, 2026 | 63,000.00 |
| Dec 31, 2025 | 12.90 Mn |
| Dec 31, 2025 | 12.90 Mn |
| Sep 30, 2025 | 281,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Jun 30, 2025 | 25.40 Mn |
| Jun 30, 2025 | 25.40 Mn |
| Mar 31, 2025 | 780,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Dec 31, 2024 | 112.18 Mn |
| Dec 31, 2024 | 112.18 Mn |
| Mar 31, 2024 | 30.00 |
| Mar 31, 2024 | 30.00 |
| Sep 30, 2023 | 92,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Jun 30, 2023 | 213,000.00 |
| Jun 30, 2023 | 213,000.00 |
| Mar 31, 2023 | 212,000.00 |
| Mar 31, 2023 | 212,000.00 |